Creative Biolabs Launches End-to-End ASO Development Services

To address stability and targeted delivery challenges in RNA therapeutics, Creative Biolabs introduces its comprehensive, one-stop antisense oligonucleotide (ASO) development platform, streamlining workflows from bioinformatic design and synthesis.

SHIRLEY, NY, June 19, 2026 /24-7PressRelease/ -- As RNA therapeutics continue to reshape the modern drug discovery landscape, researchers developing antisense oligonucleotides (ASOs) often face technical bottlenecks that can slow translational development. Designing candidates with high binding affinity, overcoming in vivo enzymatic degradation, and achieving tissue-specific delivery remain formidable industry challenges.

To bridge these gaps and accelerate pipeline progression, Creative Biolabs has announced the launch of its integrated, one-stop antisense oligonucleotide (ASO) development services. This multi-dimensional platform combines advanced bioinformatics, chemical synthesis, and rigorous preclinical validation to support global biotechnology companies and academic institutions.

Overcoming the Core Hurdles of ASO Therapeutics
Traditional ASO development is often fragmented, forcing researchers to coordinate with multiple vendors for design, synthesis, and animal testing. This lack of integration leads to extended timelines and data inconsistency. Creative Biolabs solves this by unifying the entire pipeline under one roof:

Proprietary Bioinformatic Optimization: Utilizing thermodynamic simulation and RNA secondary structure accessibility prediction to identify optimal target regions, mitigating off-target risks from the outset.
• Advanced Chemical Modification & Synthesis: Offering versatile oligonucleotide architectures, including Gapmers and steric-blocking oligos. Capabilities span from milligram to multi-gram scales, utilizing PS backbones, PMO, and sugar modifications (2'-MOE, cEt) to improve nuclease resistance and support in vivo stability.
• Precision Delivery & Conjugation: Solving the cellular uptake barrier through custom targeted delivery technologies. This includes GalNAc conjugation for liver targeting, Antibody-Oligonucleotide Conjugates (AOCs) for extrahepatic tissues, and specialized LNP formulations.
• Robust Preclinical Validation: Providing data-rich in vitro screening (mRNA knockdown via qPCR, cytotoxicity testing) and in vivo PK/PD profiling to support preclinical candidate selection and further development planning.

"Many therapeutic pipelines stall because a high-affinity sequence fails under physiological conditions due to poor delivery or low stability," stated the Chief Scientific Officer at Creative Biolabs. "Our one-stop platform eliminates these silos. By matching customized chemical modifications with precise conjugation chemistries early in the design phase, we significantly lower required doses and improve the safety profiles of our clients' candidates."

With a robust portfolio of ready-to-use ASO products spanning oncology, genetic disorders, and neuromuscular diseases, Creative Biolabs provides the flexibility and technical expertise required to turn therapeutic concepts toward preclinical candidate development.

Are you facing delivery or stability challenges with your ASO candidates? Contact our scientific team today for a technical consultation and custom quote. https://www.creative-biolabs.com/gene-therapy/.

About Creative Biolabs
Creative Biolabs is a leading global Contract Research Organization (CRO) dedicated to accelerating drug discovery and preclinical development. Creative Biolabs specializes in providing end-to-end ASO services—spanning proprietary bioinformatic design, advanced chemical synthesis, custom GalNAc/AOC conjugation, and robust in vitro/in vivo validation. Backed by a team of world-class scientists and state-of-the-art technologies, Creative Biolabs empowers biopharmaceutical companies and academic institutions worldwide to seamlessly transition therapeutic concepts into viable clinical candidates.

Read the full story here: https://www.24-7pressrelease.com/press-release/535995/creative-biolabs-launches-end-to-end-aso-development-services

Press Release Service and Press Release Distribution by 24-7 Press Release Newswire